Targeting immune cells to improve treatment for bacterial sepsis
Official title: Targeting macrophage maladaptation for bacterial sepsis treatment
Funded at Acepre, LLC · NIH-10868528 · Data updated 2026-11-12
This study is looking at how certain immune cells, called macrophages, act during bacterial sepsis, a serious condition that can cause organ failure, to find new ways to help patients recover better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Acepre, LLC NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | June 15, 2023 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $297,328 |
| NIH project number | 5R41AI174362-02 |
| Project ID | NIH-10868528 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with bacterial sepsis who are experiencing severe inflammatory responses.
✕Less likely to help
Patients with non-bacterial infections or those who are not in the acute phase of sepsis may not benefit from this research.
What this research studies
This research investigates how immune cells called macrophages behave during bacterial sepsis, a severe condition that can lead to organ failure and death. It focuses on two critical phases of sepsis: the initial hyperinflammatory response and the subsequent immunosuppression. By understanding the role of macrophages in these phases, the research aims to develop new treatment strategies that could improve patient outcomes. The approach involves studying the cellular mechanisms and metabolic changes in macrophages to identify potential therapeutic targets.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for bacterial sepsis, potentially reducing mortality rates and improving recovery times.
How similar studies have gone: Previous research has shown promise in targeting immune responses in sepsis, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Acepre, LLC
Columbia, United States Active
Researchers
- Principal investigator: Zhu, Xuewei — Acepre, LLC
- Study coordinator: Zhu, Xuewei
Related research
Other NIH-funded projects on the same topics.
-
Role of blood flow mechanics and transfusion in sepsis-related tiny-cl vessel clots
A patient-focused look at how red blood cell flow and transfusions might influence tiny blood vessel clots and organ problems in sepsis.
-
STeroids and enhanced Antibiotics for sepsis in Africa with HIV/TB (STARS)
This grant tests whether adding steroids and stronger antibiotics helps adults with severe sepsis tied to HIV/TB in areas with high TB rates.
-
Steroids and better antibiotics for sepsis in people with AIDS in Africa
This study tests whether adding hydrocortisone and stronger antibiotics can improve survival for adults with sepsis who also have AIDS or advanced immune suppression in regions with high TB.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Role of MMP3 in heart dysfunction during sepsis
This research tests whether blocking MMP3 can protect the heart and improve survival during sepsis in adults.
-
Sepsis patient care guided by Ugandan-wide immune profiling
A large NIH-funded study will map how the immune system behaves during sepsis in people in Uganda to improve personalized care for sepsis patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.